Lupus
3 years ago
#ACR21 #Abstr0454 Mortality rate in #lupus nephritis ⬇️by 26% from 1999-2019👏. BUT, racial and residence disparities were concerning; worse in Black, Hispanic, Asian, AI/AN vs White and in large central and medium metro. Residential matters! @RheumNow https://t.co/33vN39acuL https://t.co/XMwN2hXJn7
3 years ago
Race/ethnicity and residence were independent risk factors for LN mortality which was higher in:
➡️Black patients
➡️Those living in central metro areas
#ACR21 Abst#0454 @RheumNow
3 years ago
#ACR21 Abst#0456. Fxnal connectivity, ⬆️ blood-brain barrier (BBB) leakage & cognitive impairment (CI) in SLE
⭐️SLE pts ⬆️♀️, older, caucasian, ⬇️ edu than controls
⭐️CI in longer disease, APS
▶️ SLE CI:⬇️Brain-wide connections, BBB permeability
https://t.co/fen9OYhWhC @Rheumnow https://t.co/DMQfWCqUhh
3 years ago
Functional MRI eval neuro-connectivity in 78 SLE pts
Cognitive impairment occurred in 48%; pts had:
👉longer disease duration
👉likely +LAC
👉abnormal fMRI
👉>blood brain barrier permeability
#ACR21 #Plenary Abstr# 0456 @rheumnow https://t.co/WI5CD73rvM
3 years ago
How about lipoprotein a as a potential biomarker for poor renal outcomes in #lupus?
Results of this study by Dr @CaoilfhionnMD and her group show that ⬆Lp(a) is strongly associated w/ proteinuria, ⬇ eGFR and ⬆PGA.
Interesting🤓
@RheumNow #ACR21 abs0327 https://t.co/MLgJ1tPJMp
3 years ago
#ACR21
Many faces of cell death
Netosis in APS and #SLE
NETs and APS
🕸️NETs are prothrombotic🕸️ https://t.co/FG3VNbQPzh
Plenary I
0454 LN mortality in the US & disparities using CDC WONDER data 1999-2019
"LN mortality exhibited profound disparities by race/ethnicity and place of residence"
https://t.co/UtMzaiL14D
#ACR21 https://t.co/C3fuq8anvR
3 years ago
Dr. Petri et al showed transition between lupus anticoagulant (-) to (+), (+) to (-), and (+) or (-) to thrombosis could be estimated by multistate Markov model.
#ACR21 Abst#0076 @RheumNow https://t.co/oIvbak4lV4
3 years ago
Machine learning predicted lupus nephritis in #SLE patients in real world data #ACR21 @RheumNow #abst0324 https://t.co/67HBT7F2GO
3 years ago
Don't wait!
DR. Petri wants us to change paradigm of how we treat aggressive lupus nephritis: early, aggressive, and multimodal. Does not matter if you add on VCS or BLMB, just don't treat LN with MMF monotherapy.
#ACR21 #GreatDebate @rheumnow https://t.co/ebSiic095h